169869-90-3

中文名称甲磺酸伊喜替康

英文名称 Exatecan mesilate

CAS 169869-90-3

分子式 C24H22FN3O4.CH4O3S

分子量 531.56

MOL 文件 169869-90-3.mol

更新日期 2024/05/23 17:26:15

169869-90-3 结构式

基本信息物理化学性质常见问题列表

基本信息

中文别名

甲磺酸依喜替康
甲磺酸伊喜替康
依沙替康甲磺酸盐
依喜替康甲磺酸盐
(1S,9S)-1-氨基-9-乙基-5-氟-9-羟基-4-甲基-2,3,9,10,13,15-六氢-1H,12H-苯并[DE]吡喃[3',4':6,7]氮茚并[1,2-B]喹啉-10,13-二酮甲磺酸盐

英文别名

DX 8951f
Exatecan Meslate
Exatecan mesilate
169869-90-3 （free base）
Exatecan?Mesylate top3
DX8951F
DX 8951F
DX-8951F
Exatecan Mesylate (DX8951f)
Exatecan (DX-8951) mesylate
DX 8951
DX 8951
169869-90-3 (FREE BASE)
(1S,9S)-1-AMINO-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLINE-10,13-DIONE MESYLATE

所属类别

生物：拮抗剂

物理化学性质

储存条件4°C, protect from light, stored under nitrogen

溶解度DMSO:7.41(Max Conc. mg/mL);13.94(Max Conc. mM)
Water:0.0(Max Conc. mg/mL);0.19(Max Conc. mM)

形态固体

稳定性吸湿性

InChIKeyBICYDYDJHSBMFS-OVCYJQQENA-N

SMILESS(O)(=O)(=O)C.N[C@H]1CCC2C(C)=C(F)C=C3N=C4C5=CC6[C@@](C(=O)OCC=6C(=O)N5CC4=C1C3=2)(O)CC |&1:6,21,r|

常见问题列表

用途

甲磺酸伊喜替康是一种DNA 拓扑异构酶 I (topoisomerase I) 抑制剂，IC50 值为 2.2 μM (0.975 μg/mL)，可用于癌症研究。

生物活性

Exatecan mesylate (DX8951f) 是一种 DNA 拓扑异构酶 I (topoisomerase I) 抑制剂，IC50 值为 2.2 μM (0.975 μg/mL)，可用于癌症研究。

靶点

Topoisomerase I

0.975 μg/mL (IC ₅₀ )

体外研究

Exatecan mesylate is a potent topoisomerase I inhibitor, with an IC ₅₀ of 0.975 μg/mL. Exatecan mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI ₅₀ s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively. Exatecan mesylate (DX-8951f) displays cytotoxic activities against PC-6, PC-6/SN2-5 cells, with mean GI ₅₀ s of 0.186 and 0.395 ng/mL, respctively. Exatecan mesylate (34 nM) stabilizes DNA-TopoI complexes in PC-6 and PC-6/SN2-5 cells.

体内研究

Exatecan mesylate (DX-8951f, 3.325-50 mg/kg, i.v.) exhibits antitumor activities in the mice model bearing tumor cells, without toxic death. Exatecan mesylate (15, 25 mg/kg, i.v.) hightly inhibits MIA-PaCa, BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3. Exatecan mesylate (15, 25 mg/kg, i.v.) also significantly suppresses BxPC-3 lymphatic metastasis and completely eliminates lung metastasis in the BxPC-3 late-stage cancer model.